高级检索
当前位置: 首页 > 详情页

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Integrated Traditional Chinese and Western Medicine Oncology, China-Japan Friendship Hospital, Beijing, China, [2]Beijing University of Chinese medicine, Beijing, China, [3]Emergency General Hospital, Beijing, China, [4]School of Clinical Medicine. Beijing University of Chinese Medicine, Beijing, China, [5]Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, [6]Department of Integrated Traditional Chinese and Western Medicine Oncology, The Fourth Central Hospital, Baoding, China
出处:
ISSN:

关键词: triple-negative breast cancer endocrine strategy steroid hormone steroid hormone receptor endocrine responsiveness

摘要:
The immunohistochemical definition of estrogen/progesterone receptors dictates endocrine feasibility in the treatment course of breast cancer. Characterized by the deficiency of estrogen receptor alpha, ER alpha-negative breast cancers are dissociated from any endocrine regimens in the routine clinical setting, triple-negative breast cancer in particular. However, the stereotype was challenged by triple-negative breast cancers' retained sensitivity and vulnerability to endocrine agents. The interplay of hormone action and the carcinogenic signaling program previously underscored was gradually recognized along with the increasing investigation. In parallel, the overlooked endocrine-responsiveness in ER alpha-negative breast cancers attracted attention and supplied fresh insight into the therapeutic strategy in an ER alpha-independent manner. This review elaborates on the genomic and non-genomic steroid hormone actions and endocrine-related signals in triple-negative breast cancers attached to the hormone insensitivity label. We also shed light on the non-canonical mechanism detected in common hormone agents to showcase their pleiotropic effects.

语种:
WOS:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2020版] 出版当年五年平均[2016-2020] 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Department of Integrated Traditional Chinese and Western Medicine Oncology, China-Japan Friendship Hospital, Beijing, China, [2]Beijing University of Chinese medicine, Beijing, China,
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)